Approval Background

Teva received EMA approval for pomalidomide (generic name) on November 14, 2024. The drug, already approved in the United States and Japan, is an immunomodulatory agent (IMiD) with demonstrated efficacy in patients with multiple myeloma. The EMA approval is expected to substantially increase patient access across Europe.

Clinical Evidence

Pomalidomide is primarily used as a second‑line therapy, and pivotal clinical trials demonstrated statistically significant improvements in overall survival (OS) and progression‑free survival (PFS). The benefit was especially pronounced in patient cohorts resistant to existing therapies. These data formed the basis for the European regulator’s approval.

Competitive Landscape

In the European market, established IMiDs such as revlimid (lenalidomide) dominate the competitive landscape. Pomalidomide offers a more potent efficacy profile and a differentiated safety profile. Moreover, it will be launched as a generic, providing price competitiveness. This positions it attractively for healthcare institutions that prioritize cost‑effectiveness relative to branded products.

Reimbursement and Market Entry Constraints

While EMA approval is a critical first step, reimbursement decisions are made on a country‑by‑country basis. Some jurisdictions may require cost‑effectiveness analyses versus existing therapies, potentially delaying formulary inclusion. Consequently, the pace of initial market penetration will be heavily influenced by national policies.

Market Size Outlook

The source does not provide a specific market‑size estimate, but the multiple myeloma therapeutics market in Europe is valued at several billion euros. The generic launch of pomalidomide and its price competitiveness are expected to contribute to an expanded market share.